The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function. (Eluminate-4)

未提供0 个研究点目标入组 118 人开始时间: 待定

适应症

试验速览

暂无简介。

•Diagnosed with Type 2 Diabetes Mellitus for at least 90 days prior to screening
•TL2i or SGLT2i-naive and other glucose lowering medication(s)
•HbA1c value:
•On stable dose of SGLT2i >_ 7.0% to <_ 10.5% (53 to 91.3 mmol/mol)
•SGLT2i-naive >_ 7.5% to <_ 10.5% (58 to 91.3 mmol/mol)
•Impaired renal function
•Body mass index (BMI) of >_ 23 kg/m2 at screening
•Stable body weight (self-reported or documented) for 90 days prior to screening

•Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
•Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
•Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
•Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
•History of acute or chronic pancreatitis
•Severe congestive heart failure (New York Heart Association IV)
•History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

发起方

未提供